Identification

Name
Zuclopenthixol
Accession Number
DB01624  (DB08919, DB08920)
Type
Small Molecule
Groups
Approved, Investigational
Description

Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.

Structure
Thumb
Synonyms
  • cis-Clopenthixol
  • Zuclopenthixol
  • Zuclopenthixolum
  • Zuclopentixol
External IDs
N05AF05
Product Ingredients
IngredientUNIICASInChI Key
Zuclopenthixol acetate349S2ZHF0585721-05-7OXAUOBQMCDIVPQ-IOXNKQMXSA-N
Zuclopenthixol decanoateTSS9KIZ5OG64053-00-5QRUAPADZILXULG-WKIKZPBSSA-N
Zuclopenthixol dihydrochloride7042692VYN58045-23-1LPWNZMIBFHMYMX-MHKBYHAFSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clopixol - Tab 10mgTablet10 mgOralHoechst Marion Roussel1995-12-311999-08-11Canada
Clopixol - Tab 25mgTablet25 mgOralHoechst Marion Roussel1995-12-311999-08-11Canada
Clopixol - Tab 40mgTablet40 mgOralHoechst Marion Roussel1995-12-311999-08-11Canada
Clopixol Acuphase - Liq Im 50mg/mlLiquid50 mgIntramuscularHoechst Marion Roussel1995-12-311999-08-11Canada
Clopixol Depot - Liq Im 200mg/mlLiquid200 mgIntramuscularHoechst Marion Roussel1995-12-311999-08-11Canada
Clopixol Depot - Liq Im 500mg/mlLiquid500 mgIntramuscularHoechst Marion Roussel1995-12-311999-08-11Canada
Clopixol Depot 200mg/mlSolution200 mgIntramuscularLundbeck Inc.1997-05-02Not applicableCanada
Clopixol Depot 500mg/mlLiquid500 mgIntramuscularLundbeck Inc.Not applicableNot applicableCanada
Clopixol Tablets 10mgTablet10 mgOralLundbeck Inc.1997-05-02Not applicableCanada
Clopixol Tablets 25mgTablet25 mgOralLundbeck Inc.1997-05-02Not applicableCanada
International/Other Brands
Acuphase (H. Lundbeck A/S) / Ciatyl-Z (Bayer Vital) / Cisordinol (H. Lundbeck A/S) / Clopixol (H. Lundbeck A/S)
Categories
UNII
47ISU063SG
CAS number
53772-83-1
Weight
Average: 400.965
Monoisotopic: 400.137611829
Chemical Formula
C22H25ClN2OS
InChI Key
WFPIAZLQTJBIFN-DVZOWYKESA-N
InChI
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
IUPAC Name
2-(4-{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1

Pharmacology

Indication

Used in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.

Associated Conditions
Pharmacodynamics

Zuclopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Mechanism of action

Zuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.

TargetActionsOrganism
AD(1A) dopamine receptor
antagonist
Human
AD(1B) dopamine receptor
antagonist
Human
AD(2) dopamine receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
UHistamine H1 receptor
antagonist
Human
Absorption

Upon reaching the body water phase, the decanoate ester is slowly released from the oil depot, which is resultantly hydrolyzed to the active substance, zuclopenthixol. The decanoate ester provides a means of slow release since zuclopenthixol itself is a short-acting drug.

Volume of distribution

20 L/kg.

Protein binding

98-99%

Metabolism

The metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity.

Route of elimination

Primarily in the feces with approximately 10% in the urine.

Half life

20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.

Clearance

approximately 0.9 L/min.

Toxicity

Although there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia.

Neuroleptic malignant syndrome may occur. Zuclopenthixol may potentiate anticholinergic effects of concurrent medications. Zuclopenthixol has a demonstrated antiemetic effect in animals, and may mask signs of toxicity due to other drug overdoses, or may mask symptoms of disease.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineZuclopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineZuclopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineZuclopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineZuclopenthixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineZuclopenthixol may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Zuclopenthixol can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
AcepromazineZuclopenthixol may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Adipiplon.Investigational
AdrafinilZuclopenthixol may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Zuclopenthixol.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Zuclopenthixol.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zuclopenthixol.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Amantadine.Approved
AmibegronZuclopenthixol may decrease the vasoconstricting activities of Amibegron.Investigational
AmikacinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneThe serum concentration of Zuclopenthixol can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideZuclopenthixol may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazZuclopenthixol may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineZuclopenthixol may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zuclopenthixol.Approved, Illicit
AmoxapineZuclopenthixol may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amperozide.Experimental
AmphetamineZuclopenthixol may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Amrinone.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Zuclopenthixol.Approved
AnisodamineZuclopenthixol may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Zuclopenthixol can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidineZuclopenthixol may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Zuclopenthixol can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Aranidipine.Approved, Investigational
ArbutamineZuclopenthixol may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Zuclopenthixol.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Articaine.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Asenapine.Approved
AtazanavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
AtomoxetineThe serum concentration of Zuclopenthixol can be increased when it is combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Zuclopenthixol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Azaperone.Investigational, Vet Approved
AzelastineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
BaclofenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Baclofen.Approved
BambuterolZuclopenthixol may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Zuclopenthixol.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Zuclopenthixol is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineZuclopenthixol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Zuclopenthixol.Approved
BioallethrinThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
BitolterolZuclopenthixol may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
BortezomibThe serum concentration of Zuclopenthixol can be increased when it is combined with Bortezomib.Approved, Investigational
BrexpiprazoleZuclopenthixol may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Zuclopenthixol.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Zuclopenthixol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Zuclopenthixol.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
BuprenorphineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zuclopenthixol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zuclopenthixol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zuclopenthixol.Approved
CanertinibThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Canertinib.Investigational
CarbamazepineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.Approved, Investigational
CelecoxibThe metabolism of Zuclopenthixol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
CeritinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Zuclopenthixol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zuclopenthixol.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Zuclopenthixol.Approved
ChlorphentermineZuclopenthixol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Zuclopenthixol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Cilnidipine.Approved, Investigational
CinacalcetThe metabolism of Zuclopenthixol can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Zuclopenthixol.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Zuclopenthixol.Approved, Investigational
CirazolineZuclopenthixol may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Zuclopenthixol.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Zuclopenthixol.Approved
ClarithromycinThe serum concentration of Zuclopenthixol can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Clemastine.Approved, Investigational
ClenbuterolZuclopenthixol may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clindamycin.Approved, Vet Approved
ClobazamThe metabolism of Zuclopenthixol can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zuclopenthixol.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
CobicistatThe serum concentration of Zuclopenthixol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Zuclopenthixol can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zuclopenthixol.Approved, Illicit
ConivaptanThe serum concentration of Zuclopenthixol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Zuclopenthixol can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyclopropane.Experimental
CyclosporineThe serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyproheptadine.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Zuclopenthixol.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Zuclopenthixol.Investigational
DarifenacinThe metabolism of Zuclopenthixol can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Darodipine.Experimental
DarunavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DelavirdineThe serum concentration of Zuclopenthixol can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Zuclopenthixol.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Dexniguldipine.Experimental
DextroamphetamineZuclopenthixol may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zuclopenthixol.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Dexverapamil.Experimental
DezocineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zuclopenthixol.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Zuclopenthixol.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol.Approved, Illicit
DihydroergotamineThe serum concentration of Zuclopenthixol can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Zuclopenthixol can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Zuclopenthixol.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Zuclopenthixol.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zuclopenthixol.Approved, Illicit
DipivefrinZuclopenthixol may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Zuclopenthixol.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Zuclopenthixol.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dixyrazine.Experimental
DL-MethylephedrineZuclopenthixol may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineZuclopenthixol may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Zuclopenthixol.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Zuclopenthixol.Approved, Investigational, Vet Approved
DopexamineZuclopenthixol may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Zuclopenthixol can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.Approved
DoxepinZuclopenthixol may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineZuclopenthixol may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe serum concentration of Zuclopenthixol can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Illicit
DronedaroneThe serum concentration of Zuclopenthixol can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Drotebanol.Experimental, Illicit
DroxidopaZuclopenthixol may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe metabolism of Zuclopenthixol can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zuclopenthixol.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Eltanolone.Investigational
EmopamilThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Emopamil.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Eperisone.Approved, Investigational
EphedraZuclopenthixol may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineZuclopenthixol may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineZuclopenthixol may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineZuclopenthixol may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Zuclopenthixol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
ErythromycinThe serum concentration of Zuclopenthixol can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Zuclopenthixol.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zuclopenthixol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zuclopenthixol.Approved, Investigational
EtafedrineZuclopenthixol may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etifoxine.Investigational, Withdrawn
EtilefrineZuclopenthixol may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etizolam.Approved
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Zuclopenthixol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etorphine.Illicit, Vet Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Zuclopenthixol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Zuclopenthixol.Approved
FelodipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Fendiline.Withdrawn
FenoterolZuclopenthixol may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Zuclopenthixol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fexofenadine.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Fish oil.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Zuclopenthixol.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Zuclopenthixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zuclopenthixol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zuclopenthixol.Approved, Illicit, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
FosamprenavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Fosamprenavir.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Zuclopenthixol.Approved
FosphenytoinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Zuclopenthixol.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Zuclopenthixol.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
GallopamilThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Zuclopenthixol.Approved, Illicit, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
GepefrineZuclopenthixol may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
GuanabenzZuclopenthixol may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Hexobarbital.Approved
HexoprenalineZuclopenthixol may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineZuclopenthixol may decrease the vasoconstricting activities of Higenamine.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
HydrocodoneZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.Approved, Illicit
HydroxyamphetamineZuclopenthixol may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zuclopenthixol.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Zuclopenthixol.Approved
IdelalisibThe serum concentration of Zuclopenthixol can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Iloperidone.Approved
ImatinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.Approved
ImipramineZuclopenthixol may increase the antihypertensive activities of Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Withdrawn
IndinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Zuclopenthixol.Withdrawn
Iofetamine I-123Zuclopenthixol may decrease the stimulatory activities of Iofetamine I-123.Approved
IsavuconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Zuclopenthixol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Isocarboxazid.Approved
IsoetarineZuclopenthixol may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
IsomethepteneZuclopenthixol may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Zuclopenthixol can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineZuclopenthixol may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineZuclopenthixol may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Zuclopenthixol.Approved, Investigational
ItraconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineZuclopenthixol may increase the QTc-prolonging activities of Ivabradine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.Approved
LacidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zuclopenthixol.Approved
LevosalbutamolZuclopenthixol may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Zuclopenthixol.Approved, Investigational
LisdexamfetamineZuclopenthixol may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Zuclopenthixol.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lomerizine.Experimental
LoperamideThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Loperamide.Approved
LopinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Zuclopenthixol.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zuclopenthixol.Approved
LorcaserinThe metabolism of Zuclopenthixol can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lormetazepam.Approved
LovastatinThe serum concentration of Zuclopenthixol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol.Approved
LuliconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Zuclopenthixol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Magnesium Trisilicate.Approved
ManidipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Menthol.Approved
MephedroneZuclopenthixol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineZuclopenthixol may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Zuclopenthixol.Approved, Vet Approved
MequitazineZuclopenthixol may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Mesoridazine.Approved, Investigational
MetaraminolZuclopenthixol may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Zuclopenthixol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineZuclopenthixol may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zuclopenthixol.Approved
MethotrimeprazineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineZuclopenthixol may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineZuclopenthixol may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Methsuximide.Approved
MethyldopaZuclopenthixol may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.Approved, Investigational
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Zuclopenthixol.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MetyrosineZuclopenthixol may increase the sedative activities of Metyrosine.Approved
MibefradilThe serum concentration of Zuclopenthixol can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.Approved, Illicit
MidodrineZuclopenthixol may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineZuclopenthixol may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Zuclopenthixol can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneZuclopenthixol may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Zuclopenthixol.Investigational
MirtazapineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Mitotane.Approved
MMDAZuclopenthixol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MolindoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zuclopenthixol.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Zuclopenthixol.Approved, Investigational
MoxonidineZuclopenthixol may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
NaftopidilThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zuclopenthixol.Approved
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Zuclopenthixol.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Zuclopenthixol.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
NefazodoneThe serum concentration of Zuclopenthixol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir.Approved
NeomycinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Neomycin.Approved, Vet Approved
NetupitantThe serum concentration of Zuclopenthixol can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Zuclopenthixol can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nifedipine.Approved
NiguldipineZuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zuclopenthixol.Approved
NitrendipineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nordazepam.Approved
NorepinephrineZuclopenthixol may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineZuclopenthixol may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Normethadone.Approved, Illicit
NortriptylineZuclopenthixol may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Zuclopenthixol.Approved
OctopamineZuclopenthixol may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
OlanzapineOlanzapine may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
OlaparibThe serum concentration of Zuclopenthixol can be increased when it is combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olopatadine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Zuclopenthixol.Approved
OpiumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Opium.Approved, Illicit
OrciprenalineZuclopenthixol may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Osanetant.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zuclopenthixol.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zuclopenthixol.Approved, Illicit, Investigational
OxyfedrineZuclopenthixol may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zuclopenthixol.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Zuclopenthixol.Approved
PanobinostatThe serum concentration of Zuclopenthixol can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Zuclopenthixol.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Zuclopenthixol.Approved
Peginterferon alfa-2bThe serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
PenfluridolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.Approved, Vet Approved
PentobarbitalThe serum concentration of Zuclopenthixol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Zuclopenthixol.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
PerazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perazine.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PergolideZuclopenthixol may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zuclopenthixol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zuclopenthixol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenazocine.Experimental
PhendimetrazineZuclopenthixol may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.Approved
PhenibutThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenibut.Experimental
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Zuclopenthixol.Approved
PhenobarbitalThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Zuclopenthixol.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenoxyethanol.Approved
PhentermineZuclopenthixol may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineZuclopenthixol may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Zuclopenthixol.Approved
PhenylpropanolamineZuclopenthixol may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Zuclopenthixol.Approved
PinaveriumThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipotiazine.Approved, Investigational
PirbuterolZuclopenthixol may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Piritramide.Approved, Investigational
PitolisantThe metabolism of Zuclopenthixol can be decreased when combined with Pitolisant.Approved, Investigational
PizotifenZuclopenthixol may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
PramipexoleZuclopenthixol may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Zuclopenthixol.Approved
PregabalinThe therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolZuclopenthixol may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PrimidoneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Zuclopenthixol.Approved
ProcaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Zuclopenthixol.Approved, Investigational
ProcaterolZuclopenthixol may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zuclopenthixol.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Zuclopenthixol.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Zuclopenthixol.Approved
PropanididThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Proparacaine.Approved, Vet Approved
PropericiazineZuclopenthixol may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Zuclopenthixol.Approved
PropiverineZuclopenthixol may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
ProtokylolZuclopenthixol may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Zuclopenthixol.Approved
PyrantelThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zuclopenthixol.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Zuclopenthixol.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Zuclopenthixol.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Zuclopenthixol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Quinisocaine.Experimental
RacepinephrineZuclopenthixol may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Raclopride.Investigational
RactopamineZuclopenthixol may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Zuclopenthixol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zuclopenthixol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zuclopenthixol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Remoxipride.Approved, Withdrawn
ReproterolZuclopenthixol may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zuclopenthixol.Approved, Investigational
RifabutinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifapentine.Approved, Investigational
RilmenidineZuclopenthixol may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
RimiterolZuclopenthixol may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ritanserin.Investigational
RitobegronZuclopenthixol may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineZuclopenthixol may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Zuclopenthixol can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Zuclopenthixol.Approved
RolapitantThe metabolism of Zuclopenthixol can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Romifidine.Vet Approved
RopiniroleZuclopenthixol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ropivacaine.Approved
RotigotineZuclopenthixol may increase the sedative activities of Rotigotine.Approved
RucaparibThe serum concentration of Zuclopenthixol can be increased when it is combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zuclopenthixol.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Zuclopenthixol.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Zuclopenthixol.Approved
SaquinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zuclopenthixol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Zuclopenthixol.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
SildenafilThe serum concentration of Zuclopenthixol can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Zuclopenthixol.Approved
SimeprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
SolabegronZuclopenthixol may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Zuclopenthixol.Approved
St. John's WortThe serum concentration of Zuclopenthixol can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Zuclopenthixol can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Zuclopenthixol.Approved
SulfisoxazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideZuclopenthixol may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Zuclopenthixol.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
SuvorexantZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineZuclopenthixol may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Zuclopenthixol.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tasimelteon.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Zuclopenthixol.Approved
TelaprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TelithromycinThe serum concentration of Zuclopenthixol can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zuclopenthixol.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Zuclopenthixol.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zuclopenthixol.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Tetrandrine.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrodotoxin.Investigational
TetryzolineZuclopenthixol may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Zuclopenthixol.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Thiopental.Approved, Vet Approved
ThioproperazineZuclopenthixol may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Thioridazine is combined with Zuclopenthixol.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiapride.Approved, Investigational
TiclopidineThe serum concentration of Zuclopenthixol can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved
TipranavirThe metabolism of Zuclopenthixol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Zuclopenthixol.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Tolfenamic Acid.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Zuclopenthixol.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zuclopenthixol.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Zuclopenthixol can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
TretoquinolZuclopenthixol may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zuclopenthixol.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Zuclopenthixol.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Trimethadione.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
TrimipramineZuclopenthixol may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
TulobuterolZuclopenthixol may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Zuclopenthixol.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Zuclopenthixol.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Valproic Acid.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vancomycin.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Zuclopenthixol.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Zuclopenthixol.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Zuclopenthixol.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Veralipride.Experimental
VerapamilThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Zuclopenthixol.Approved
VinpocetineThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Zuclopenthixol is combined with WIN 55212-2.Experimental
XamoterolZuclopenthixol may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Xylazine.Vet Approved
XylometazolineZuclopenthixol may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zuclopenthixol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Zuclopenthixol can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zuclopenthixol.Approved, Investigational
ZolpidemZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Zuclopenthixol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zotepine.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216]
  2. Fond G, Macgregor A, Tamouza R, Hamdani N, Meary A, Leboyer M, Dubremetz JF: Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):179-83. doi: 10.1007/s00406-013-0413-4. Epub 2013 Jun 15. [PubMed:23771405]
  3. Jayakody K, Gibson RC, Kumar A, Gunadasa S: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2012 Apr 18;4:CD000525. doi: 10.1002/14651858.CD000525.pub3. [PubMed:22513898]
  4. Nielsen MK, Johansen SS: Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2012 Sep;36(7):497-506. doi: 10.1093/jat/bks054. Epub 2012 Jun 19. [PubMed:22718540]
  5. Khalifa AE: Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. Hum Exp Toxicol. 2004 Aug;23(9):439-45. [PubMed:15497819]
  6. Hood S, Orr K, Bennett L, Davies S: Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. Australas Psychiatry. 2010 Apr;18(2):174-6. doi: 10.3109/10398560903473686. [PubMed:20175668]
  7. Link [Link]
  8. Link [Link]
External Links
Human Metabolome Database
HMDB0015561
KEGG Drug
D03556
PubChem Compound
5311507
PubChem Substance
46507341
ChemSpider
4470984
BindingDB
79209
ChEBI
51364
ChEMBL
CHEMBL53904
Therapeutic Targets Database
DAP000845
PharmGKB
PA452629
Drugs.com
Drugs.com Drug Page
Wikipedia
Zuclopenthixol
ATC Codes
N05AF05 — Zuclopenthixol
AHFS Codes
  • 28:16.08.32 — Thioxanthenes
FDA label
Download (229 KB)
MSDS
Download (568 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4TerminatedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral40 mg
LiquidIntramuscular50 mg
LiquidIntramuscular200 mg
LiquidIntramuscular500 mg
SolutionIntramuscular200 mg
TabletOral10 mg
TabletOral25 mg
SolutionIntramuscular50 mg
Prices
Unit descriptionCostUnit
Clopixol Acuphase 50 mg/ml16.52USD ml
Clopixol Depot 200 mg/ml16.52USD ml
Clopixol 25 mg Tablet1.06USD tablet
Clopixol 10 mg Tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)~50http://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
water solubilityslighthttp://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
Predicted Properties
PropertyValueSource
Water Solubility0.0026 mg/mLALOGPS
logP4.46ALOGPS
logP4.22ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9443
Blood Brain Barrier+0.9676
Caco-2 permeable-0.5313
P-glycoprotein substrateSubstrate0.8762
P-glycoprotein inhibitor IInhibitor0.8736
P-glycoprotein inhibitor IIInhibitor0.7439
Renal organic cation transporterInhibitor0.5829
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6722
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.7518
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8213
Ames testNon AMES toxic0.7617
CarcinogenicityNon-carcinogens0.9029
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity2.8877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6099
hERG inhibition (predictor II)Inhibitor0.7023
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (140 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiopyrans
Sub Class
1-benzothiopyrans
Direct Parent
Thioxanthenes
Alternative Parents
Diarylthioethers / N-alkylpiperazines / Benzenoids / Aryl chlorides / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organochlorides
show 1 more
Substituents
Thioxanthene / Diarylthioether / Aryl thioether / N-alkylpiperazine / Aryl chloride / Aryl halide / 1,4-diazinane / Piperazine / Benzenoid / Tertiary aliphatic amine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
clopenthixol (CHEBI:51364)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319]
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. [PubMed:10222441]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319]
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. [PubMed:10222441]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G: Conventional and atypical antipsychotics in the elderly : a review. Clin Drug Investig. 2003;23(5):287-322. [PubMed:17535043]
  2. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319]
  3. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. [PubMed:8748043]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. [PubMed:8748043]
  2. Gjerden P, Slordal L, Bramness JG: Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol. 2009 Dec;65(12):1229-35. doi: 10.1007/s00228-009-0696-6. [PubMed:19644682]
  3. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Link [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on August 29, 2007 14:18 / Updated on August 15, 2018 09:52